Case Reports in Cardiology / 2018 / Article / Tab 1

Case Report

Decitabine Induced Delayed Cardiomyopathy in Hematologic Malignancy

Table 1

Baseline characteristics of patients.

Age/sexComorbid conditionsDecitabineEF 1aBiomarkerTestbEF 2cEF Δd

De et al. [6] (2012)75 yrs/MDM type II, DVT2 cycles35%BNP: 259Coronary angiogram50% (after 7 days)Yes
Our patient71 yrs/FHTN, Hep B, hypothyroidism10 cycles28%Pro-BNP: 517Nuclear stress test28% (after 4 weeks) but with improvement in strainNo

aBaseline left ventricular ejection fraction. bTest to rule out coronary artery disease. cRepeat left ventricular ejection fraction. dReversibility of ejection fraction. Note: both patients received decitabine as part of treatment for acute myeloid leukemia. Abbreviations: BNP: brain natriuretic peptide; DM: diabetes mellitus; DVT: deep vein thrombosis; EF: ejection fraction; HTN: hypertension; Hep B: hepatitis B; BNP units: pg/ml.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.